IFN beta-1a in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Davoudi-Monfared, 2020 0.30 [0.11; 0.83]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
0.70 [0.13 ; 3.86 ] Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021 2 79% 1,050 serious not evaluable deathsdetailed results Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
0.76 [0.17 ; 3.38 ] Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021 2 75% 1,061 serious not evaluable deaths (time to event analysis only)detailed results Davoudi-Monfared, 2020 0.38 [0.16; 0.87]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
0.76 [0.17 ; 3.38 ] Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021 2 75% 1,061 serious not evaluable clinical improvementdetailed results Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
1.00 [0.88 ; 1.13 ] Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021 2 0% 1,050 moderate not evaluable clinical improvement (14-day)detailed results Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
1.01 [0.79 ; 1.29 ] Kalil (ACTT-3), 2021 1 0% 969 NA not evaluable clinical improvement (time to event analysis only)detailed results Davoudi-Monfared, 2020 1.10 [0.64; 1.88]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
1.00 [0.88 ; 1.13 ] Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021 2 0% 1,050 moderate not evaluable hospital dischargedetailed results Davoudi-Monfared, 2020 1.96 [0.76; 5.03]
1.96 [0.76 ; 5.03 ] Davoudi-Monfared, 2020 1 0% 81 NA not evaluable mechanical ventilationdetailed results Davoudi-Monfared, 2020 0.72 [0.29; 1.76]
0.72 [0.29 ; 1.76 ] Davoudi-Monfared, 2020 1 0% 81 NA not evaluable off oxygenationdetailed results Davoudi-Monfared, 2020 8.57 [1.43; 51.36]
8.57 [1.43 ; 51.36 ] Davoudi-Monfared, 2020 1 0% 32 NA not evaluable superinfectiondetailed results Davoudi-Monfared, 2020 2.41 [0.75; 7.73]
2.41 [0.75 ; 7.73 ] Davoudi-Monfared, 2020 1 0% 81 NA not evaluable 0.5 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-10 01:41 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 881,904
- roots T: 290